A COMPARATIVE STUDY OF TLR7 EXPRESSION IN DIFFERENT HISTOLOGICAL GRADES OF ORAL SQUAMOUS CELL CARCINOMA (An Immunohistochemical Study)

Document Type : Original Article

Authors

1 Assistant lecturer in Oral Pathology Department, Faculty of Dentistry, Pharos University

2 Professor in Oral Pathology Department, Faculty of Dentistry, Alexandria University

3 Professor in Oral Pathology Department, Faculty of Dentistry, Alexandria University.

4 Assistant Professor in Physiology Department, Faculty of Medicine, Alexandria University

5 Lecturer in Oral Pathology Department, Faculty of Dentistry, Alexandria University

Abstract

INTRODUCTION: Oral squamous cell carcinoma (OSCC) accounts for the sixth most prevalent malignant neoplasm worldwide, representing 90% of all oral cancers. Despite advances in the detection and treatment, the unsatisfactory prognosis for OSCC has remained stable for decades. To date, cancer research is focused on improving cancer treatment methods using immunotherapy. The Toll-like receptors family (TLR) has served that purpose. These are a family of pattern recognition receptors (PRRs) that represent essential components of the host’s immune responses. The expression of some TLRs, including TLR7, in different tumors has been confirmed in various studies. The clarification of the TLR7 expression and role in OSCC may thus provide new strategies and prospects for more effective cancer diagnosis and treatment. OBJECTIVES: To evaluate the expression of TLR7 in human OSCC and correlate it with the different histopathological grades of the tumor. MATERIALS AND METHODS: The TLR7 expression was examined in 10 normal mucosal and 30 OSCC tissue samples. The immunohistochemical (IHC) staining with the anti-TLR7 antibody was performed using the Labeled Strept-Avidin Biotin complex method (LSAB). RESULTS: TLR7 was expressed in all OSCC cases and showed significant difference in its expression among the different grades of the tumor, with a higher expression noted in the more differentiated tumors. CONCLUSIONS: The expression of TLR7 in OSCC may be used as a prognostic marker.

Keywords

References

  1. Siegel R, Ma JM, Zou ZH, Jemal A. Cancer statistics. 2014. Ca Cancer J Clin. 2014;64:9-29.
  2. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884-94.
  3. Kujan O, Farah C, Johnson N. Oral and oropharyngeal cancer in the Middle East and North Africa: Incidence, mortality, trends, and gaps in public databases as presented to the Global Oral Cancer Forum. Transl Res Oral Oncol. 2017;2.
  4. Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017;70:23-8.
  5. Smitha T, Mohan CV, Hemavathy S. Clinicopathological features of oral squamous cell carcinoma: A hospital-based retrospective study. J NTR Univ Health Sci. 2017;6:29-34.
  6. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. Nat immunol. 2010;11;373-84.
  7. Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Internat Rev Immunol. 2018;37:20-36.
  8. McClure R, Massari P. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol. 2014;5:386.
  9. Voogdt C, Van Putten J. Chapter 13: The Evolution of the Toll-Like Receptor System. In: The Evolution of the Immune System. Elsevier Inc: Academic Press, Italy. 2016;p.311-30.
  10. Pradere JP, Dapito DH, Schwabe RF. The yin and yang of toll-like receptors in cancer. Oncogene. 2014;33:3485-95.
  11. Rich AM, Hussaini HM, Parachuru VPB, Seymour GJ. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol. 2014;5:464.
  12. Rydberg C, Månsson A, Uddman R, Riesbeck K, Cardell L-O. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunol. 2009;128:600-11. 
  13. Pakdel F, Pouralibaba F, Pakdel S, Khiyavi RK, Falsafi P, Eslami H, et al. Expression of toll-like receptors in squamous cell carcinoma of the tongue. Arch Appl Sci Res. 2015;7:20-4.
  14. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-9.
  15. Ahn MY, Kwon SM, Cheong HH, Park JH, Lee J, Min SK, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 2012;41:540-6.
  16. Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 2012;18:6668-78.
  17. Dajon M, Iribarren K, Cremer I. Dual roles of TLR7 in the lung cancer microenvironment. OncoImmunol. 2015;4:e991615.
  18. Grimmig T, Matthes N, Hoeland K, Tripathi S, Chandraker A, Grimm M, et al. TLR7 and TLR8expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol. 2015;47:857-66.
  19. Syrbu SI, Cohen MB. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalinfixed, paraffin-embedded tissues. Methods Mol Biol. 2011;717:101-10.
  20. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.
  21. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. Molecular pathways: toll-like receptors in the tumor microenvironment – poor prognosis or new therapeutic opportunity. Clin Cancer Res. 2013;19:1340- 6.
  22. Burns EM, Yusuf N. Toll-like receptors and skin cancer. Front Immunol. 2014;5:135.
  23. Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: a pro- and anti-tumor doubleedged sword. Immunobiol. 2017;222:89-100.
  24. Sugawara Y, Uehara A, Fujimoto Y, Kusumoto S, Fukase K, Shibata K, et al. Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res. 2006;85:524- 9.
  25. Beklen A, Hukkanen M, Richardson R, Konttinen YT. Immunohistochemical localization of Toll-like receptors 1-10 in periodontitis. Oral Microbiol Immunol. 2008;23:425-31.
  26. Helminen O, Huhta H, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Nucleic acid-sensing tolllike receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma. Oncoimmunol. 2016;5:e1127495.
  27. Huhta H, Helminen O, Kauppila JH, Salo T, Porvari K, Saarnio J, et al. The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer. J Histochem Cytochem. 2016;64:470-82.
  28. Mäkinen LK, Ahmed A, Hagstrom J, Lehtonen S, Makitie AA, Salo T, et al. Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. J Oral Pathol Med. 2016;45:338-45.
  29. Mahanonda R, Pichyangkul S. Toll-like receptors and their role in periodontal health and disease. Periodontol 2000. 2007;43:41-55.
  30. Ali A, Natah S, Konttinen Y. Differential expression of Toll-like receptors in chronic hyperplastic candidosis. Oral Microbiol Immunol. 2008;23:299-307.
  31. Kotrashetti VS, Nayak R, Bhat K, Hosmani J, Somannavar P. Immunohistochemical expression of TLR4 and TLR9 in various grades of oral epithelial dysplasia and squamous cell carcinoma, and their roles in tumor progression: a pilot study. Biotech Histochem. 2013;88:311-22.
  32. Park J-H, Yoon H-E, Jeon D-I, Ahn S-G, Yoon J-H. Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD10B cells. J Oral Pathol Med. 2010;39:781-5.
  33. Mäkinen L, Atula T, Häyry V, Jouhi L, Datta N, Lehtonen S, et al. Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol. 2015;51:96-102.
  34. Zujun S , Qingqiong L , Dongxia Y , Wantao C , Fuxiarng C. Role of toll-like recep 4 on the immune escape of human OSCC and resistance of cisptatin induced apoptosis . Mol Can. 2012;11:33-6.
  35. Takala H, Kauppila JH, Soini Y, Selamder KS, Lehenkari PP, Saamio J, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 2011;3:631-8.
  36. Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathol. 2015;67:730-9.
  37. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:3745-51.
  38. Huang B , Zhao J , Unkeless JC , Feng ZH , Xiong H. TLR signaling by tumor and immune cells: a double edged sword . Oncogene. 2008;27:218-24.
  39. Connolly DJ, O’Neill LA. New developments in Tolllike receptor targeted therapeutics. Curr Opin Pharmacol. 2012;12:510-8.
Alexandria Dental Journal
Volume 43, Issue 3
December 2018
Pages 70-75

Files

Share

How to cite

Statistics